{
    "title": "EpiPen maker Mylan forecasts strong 2017; shares jump",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-4271328/Generic-drugmaker-Mylans-profit-benefits-Meda-buy.html",
    "date": "2017-03-01",
    "keywords": [
        "profit",
        "share",
        "mylan",
        "revenue",
        "forecast",
        "pressure",
        "drugmaker",
        "year",
        "wednesday",
        "pricing",
        "percent",
        "price",
        "company",
        "analyst",
        "expectation",
        "version",
        "grovermarch",
        "allergy",
        "shot",
        "maker",
        "contrast",
        "fourthquarter",
        "demand",
        "purchase",
        "trading",
        "fire",
        "treatment",
        "generic",
        "product",
        "state",
        "programsthe",
        "midsingle",
        "percentage",
        "erosion",
        "wellstill",
        "report",
        "picture",
        "capital",
        "randall",
        "saidthe",
        "december",
        "billion1375",
        "midpoint",
        "thomson",
        "teva",
        "pharma",
        "co",
        "plc",
        "goldman",
        "sachs",
        "advair",
        "inhaler",
        "blockbuster",
        "sclerosis",
        "drug",
        "copaxone",
        "mg",
        "approvedmylan",
        "quarter",
        "estimate",
        "billionreporting",
        "grover",
        "bengaluru",
        "editing",
        "dsouza",
        "sai",
        "sachin",
        "ravikumar"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}